Mandate

VINGE ADVISES THE AIRPORT OPERATOR ABERTIS IN CONNECTION WITH THE SALE OF STOCKHOLM SKAVSTA AIRPORT

July 25, 2013

Vinge has advised the Spanish airport operator, Abertis Infraestructuras S.A. in connection with the sale of the British subsidiary, TBI, and its subsidiary, Stockholm Skavsta Flygplata AB. Stockholm Skavsta Flygplats is being sold together with airports in Belfast and Orlanda Sanford (Florida) airport terminal as well as TBI’s other management operations at airports in the United States to the North American airport operator, ADC & HAS Airports Worldwide. Stockholm Skavsta airport is Sweden’s third largest airport with approximately 2.5 million passengers per year. The airport has been owned by Abertis since 2005. The municipality of Nyköping will continue to hold 9.9% of the shares in Stockholm Skavsta Flygplats AB. The transaction is conditional upon approval by the relevant competition authorities and other public authorities.

Vinge’s team consisted of partner Michael Wigge together with, among others, associates Paul Dali (M&A), Johan Cederblad (real estate and environmental) and Åsa Gotthardsson (employment and pensions).

Related

Vinge advises Trianon in connection with directed share issue and tender offer for subordinated sustainable capital securities

Vinge advises Fastighets Aktiebolaget Trianon (publ) in connection with a directed share issue of SEK 184 million and a tender offer for outstanding subordinated perpetual floating rate callable sustainable capital securities.
April 19, 2024

Vinge advises Blackstone in connection with its investment in Winthrop Technologies

Vinge, as local Swedish counsel, advised Blackstone Tactical Opportunities and affiliated funds (“Blackstone”) in connection with a strategic partnership with Winthrop Technologies Limited (“Winthrop Technologies”).
April 17, 2024

Vinge has advised Hansa Biopharma in connection with a directed share issue of SEK 372 million

Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of SEK 372 million before transaction costs. Hansa Biopharma is a commercial-stage biopharmaceutical company pioneering the development and commercialization of innovative, lifesaving and life altering treatments for patients with rare immunological conditions. Hansa Biopharma’s ordinary share is listed on Nasdaq Stockholm.
April 16, 2024